The British pharmaceutical powerhouse GSK has made a significant move by agreeing to purchase the U.S.-based cancer medication firm Nuvalent in a $10.6 billion cash transaction, representing its largest acquisition in several years. This deal assigns Nuvalent a value of $124 per share, which is a 40% increase from its last closing price. GSK stated that this acquisition will bolster its lung cancer treatment offerings and facilitate growth as it anticipates upcoming patent expirations for crucial HIV treatments. In 2025, GSK's oncology revenue surged by 43% to almost £2 billion, underscoring the company's intensified focus on cancer treatments and rivalry with AstraZeneca.
